Galinpepimut-S

SELLAS Life Sciences anticipates 2025 milestones, including Phase 3 REGAL study interim analysis for AML, full Phase 2 SLS009 data in AML, and FDA feedback. SLS009, now named tambiciclib, shows promise in AML with ASXL1 mutations. Regulatory designations highlight unmet needs in pediatric AML and ALL. SELLAS to host a 2025 business update webinar.

SELLAS Life Sciences Group updates on cancer therapies progress, with key 2025 milestones for its Phase 3 REGAL study in AML and Phase 2 trial of SLS009. GPS and SLS009 received FDA designations, showing promise in treating hematologic malignancies. SELLAS maintains a strong financial position, focusing on advancing its clinical portfolio.

SELLAS Life Sciences Group reached the 60-event threshold in its Phase 3 REGAL trial of galinpepimut-S (GPS) for AML, triggering an interim analysis by the Independent Data Monitoring Committee in January 2025. The analysis will assess GPS's efficacy, futility, and safety.

SELLAS Life Sciences Group advances in Phase 3 REGAL trial for AML, reaching a key milestone with 60 events prompting an interim analysis by IDMC in January 2025. The trial evaluates galinpepimut-S (GPS) targeting WT1 protein. SELLAS also develops SLS009, showing promise in AML. Recent developments include positive Phase 2 results for SLS009, FDA designations, and financial strategies to support R&D.

SELLAS Life Science's Phase 3 REGAL trial for galinpepimut-S in AML reaches 60-event threshold, prompting IDMC's interim analysis.

SELLAS Life Sciences reports promising Phase 2 trial results for SLS009 in treating r/r AML, showing median overall survival exceeding 7.7 months and a 56% ORR in AML MRC patients. The drug is well-tolerated, with no new safety concerns. SELLAS is financially stable, supporting ongoing clinical development.